ImmunoCellular plummets on ICT-107 Phase II miss

ImmunoCellular Therapeutics tried to put a positive spin on statistically significant progression-free survival (PFS) for newly-diagnosed glioblastoma multiforme patients treated with the dendritic cell-based cancer vaccine ICT-107 in a Phase II clinical trial, but the company's stock dropped by more than half based on the trial's missed overall survival (OS) primary endpoint.